In a regulatory filing, Catalyst Pharmaceuticals (CPRX) president and CEO Richard Daly disclosed the purchase of 70,000 common shares of the company on May 30 at a price of $24.86 per share.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Catalyst Pharma Appoints New Chief Medical Officer
- Catalyst Pharmaceuticals appoints William Andrews as CMO
- Catalyst Pharma Holds 2025 Annual Stockholders Meeting
- Catalyst Pharma’s Strong Commercial Performance and Promising Revenue Guidance Justify Buy Rating
- Catalyst Pharma’s Strong Growth Prospects and Strategic Initiatives Drive Buy Rating